IJCS | Volume 32, Nº1, January/ February 2019

81 Figure 8 - NT-proBNP (A) and hs-cTnT (B) concentrations in “patients with and those without significant (> 10%) hibernation. Median (interquartile range) values of (A) serum NT-proBNP and (B) hs-cTnT levels are shown at the top of each corresponding bar.” – Adapted with permission from Zelt et al., Can J Cardiol 58 NT-proBNP (Log of serum N-terminal pro b-type natriuretic peptide), hs-cTnT (high-sensitivity cardiac troponin T). 1. MozaffarianD, Benjamin EJ, Go AS, Arnett DK, BlahaMJ, CushmanM, et al; AmericanHeart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29322. Erratum in: Circulation. 2016;133(8):e417. Circulation. 2015;131(24):e535. 2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. 3. Brasil. Ministério da Saúde. Mortalidade TabNet Win32 3.0. [Acesso em 2017 nov 16]. Disponível em: http://tabnet.datasus.gov.br/cgi/tabcgi. exe?sim/cnv /obt10uf.de. 4. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31(24):2984-95. 5. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375-410. 6. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease. a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(20):2002-12. 7. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al; PARR-2 Investigators. Increasing benefit from revascularization is associatedwith increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2(9):1060-8. 8. Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, et al; PARR 2 Investigators. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51(4):567-74. 9. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151-8. 10. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92(12):3436-44. 11. Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, et al; PARR 2 Investigators. Long-term follow-up of outcomes with F-18- fluorodeoxyglucose positron emission tomography imaging–assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circ Cardiovasc Imaging. 2016;9(9). pii: e 004331. 12. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363-72. 13. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73(8):527-33. 14. Lim SP, McArdle BA, Beanlands RS, Hessian RC. Myocardial viability: it is still alive. Semin Nucl Med. 2014;44(5):358-74. References Erthal et al. Myocardial viability: from PARR-2 to IMAGE HF - current evidence and future directions Int J Cardiovasc Sci. 2019;32(1)70-83 Review Article Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors.